ASPP proteins discriminate between PP1 catalytic subunits through their SH3 domain and the PP1 C-tail
AuthorBertran, M Teresa
Kumar, Ganesan Senthil
van Drogen, Audrey
Banerjee, Jennifer J
AffiliationUniv Arizona, Dept Chem & Biochem
MetadataShow full item record
PublisherNATURE PUBLISHING GROUP
CitationBertran, M. T., Mouilleron, S., Zhou, Y., Bajaj, R., Uliana, F., Kumar, G. S., ... & O’Reilly, N. (2019). ASPP proteins discriminate between PP1 catalytic subunits through their SH3 domain and the PP1 C-tail. Nature communications, 10(1), 771.
Rights© The Author(s) 2019.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractSerine/threonine phosphatases such as PP1 lack substrate specificity and associate with a large array of targeting subunits to achieve the requisite selectivity. The tumour suppressor ASPP (apoptosis-stimulating protein of p53) proteins associate with PP1 catalytic subunits and are implicated in multiple functions from transcriptional regulation to cell junction remodelling. Here we show that Drosophila ASPP is part of a multiprotein PP1 complex and that PP1 association is necessary for several in vivo functions of Drosophila ASPP. We solve the crystal structure of the human ASPP2/PP1 complex and show that ASPP2 recruits PP1 using both its canonical RVxF motif, which binds the PP1 catalytic domain, and its SH3 domain, which engages the PP1 C-terminal tail. The ASPP2 SH3 domain can discriminate between PP1 isoforms using an acidic specificity pocket in the n-Src domain, providing an exquisite mechanism where multiple motifs are used combinatorially to tune binding affinity to PP1.
NoteOpen access journal
VersionFinal published version
SponsorsFrancis Crick Institute; Cancer Research UK [FC001175]; UK Medical Research Council [FC001175]; Wellcome Trust [FC001175, 107885/Z/15/Z]; NIH [R01-GM098482, R01-NS091336]; European Union 7th Framework Programme SYBILLA (Systems Biology of T-Cell Activation); Innovative Medicines Initiative project ULTRA-DD